BioSpace News Archive

EB8018 was found to be well tolerated in healthy volunteers across a wide range of doses tested

Diluted earnings per share for the third quarter was $0.20 based on net income of $2.9 million, compared to third quarter 2016 net income of $3.2 million and diluted earnings per share of $0.22.

Net sales were $105.2 million, diluted earnings per share from continuing operations was $0.18 and adjusted earnings per share from continuing operations was $0.42.

The Rare Pediatric Disease Designation of 9-ING for the treatment of pediatric neuroblastoma comes in addition to Orphan Drug Designations previously granted by the FDA for neuroblastoma, and separately,

The Company will conduct an earnings call at 8:00 am EST on Wednesday, November 8, 2017, where senior management will discuss the Company’s performance and answer questions from participants.

Revenues for the third quarter of 2017 decreased three percent to $44M, compared to $45.3M for the third quarter of 2016.

AcelRx today announced that it will release third quarter financial results after market close on Thursday, November 9th.

Impax announced today the commencement of a consent solicitation with respect to its 2.00% Convertible Senior Notes due 2022.

Sales in the first six months of FY2017 decreased by 1.8% compared to those in the corresponding period of the previous fiscal year (“year-on-year”) to JPY639.8 billion due to the impact of certain items such as the transfer of the global dermatology business in April 2016 and the transfer of long-listed products in Japan in April 2017.

The approval will enable BIOPHYTIS to begin the SARA-INT interventional study in five clinical centers in the United States.